FR2910814B1 - Utilisation du 10-°(r3)-1-azabicyclo°2.2.2!oct-3-ylmethyl!-10h- phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1,2,3 - Google Patents

Utilisation du 10-°(r3)-1-azabicyclo°2.2.2!oct-3-ylmethyl!-10h- phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1,2,3

Info

Publication number
FR2910814B1
FR2910814B1 FR0656002A FR0656002A FR2910814B1 FR 2910814 B1 FR2910814 B1 FR 2910814B1 FR 0656002 A FR0656002 A FR 0656002A FR 0656002 A FR0656002 A FR 0656002A FR 2910814 B1 FR2910814 B1 FR 2910814B1
Authority
FR
France
Prior art keywords
phenothiazine
ylmethyl
medicament
oct
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0656002A
Other languages
English (en)
French (fr)
Other versions
FR2910814A1 (fr
Inventor
Thierry Clerc
Versailles Jacky Tisne
Christophe Przybylski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0656002A priority Critical patent/FR2910814B1/fr
Priority to TW096147644A priority patent/TWI423806B/zh
Priority to PCT/EP2007/064553 priority patent/WO2008080924A1/fr
Priority to KR1020097013047A priority patent/KR101465277B1/ko
Priority to BRPI0720591-0A priority patent/BRPI0720591A2/pt
Priority to UAA200907928A priority patent/UA98131C2/ru
Priority to JP2009543465A priority patent/JP5564263B2/ja
Priority to US12/521,067 priority patent/US8143245B2/en
Priority to CA002674162A priority patent/CA2674162A1/fr
Priority to MX2009006950A priority patent/MX2009006950A/es
Priority to NZ577915A priority patent/NZ577915A/en
Priority to AU2007341274A priority patent/AU2007341274B2/en
Priority to HK10100843.7A priority patent/HK1133207B/xx
Priority to CN2007800467680A priority patent/CN101573120B/zh
Priority to EP07858150A priority patent/EP2124956A1/fr
Priority to RU2009128326/15A priority patent/RU2449794C2/ru
Priority to ARP070105989A priority patent/AR064714A1/es
Publication of FR2910814A1 publication Critical patent/FR2910814A1/fr
Priority to ZA200904304A priority patent/ZA200904304B/xx
Priority to TNP2009000257A priority patent/TN2009000257A1/fr
Priority to IL199557A priority patent/IL199557A/en
Priority to MA32046A priority patent/MA31026B1/fr
Priority to NO20092654A priority patent/NO20092654L/no
Priority to FR1152199A priority patent/FR2953721A1/fr
Application granted granted Critical
Publication of FR2910814B1 publication Critical patent/FR2910814B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR0656002A 2006-12-28 2006-12-28 Utilisation du 10-°(r3)-1-azabicyclo°2.2.2!oct-3-ylmethyl!-10h- phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1,2,3 Expired - Fee Related FR2910814B1 (fr)

Priority Applications (23)

Application Number Priority Date Filing Date Title
FR0656002A FR2910814B1 (fr) 2006-12-28 2006-12-28 Utilisation du 10-°(r3)-1-azabicyclo°2.2.2!oct-3-ylmethyl!-10h- phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1,2,3
TW096147644A TWI423806B (zh) 2006-12-28 2007-12-13 １０-〔（３ｒ）-１-氮雜雙環〔２，２，２〕辛-３-基甲基〕-１０ｈ-啡噻供製備發揮ｍ１、ｍ２及ｍ３蕈毒素受體選擇性抑制作用之藥物的用途
RU2009128326/15A RU2449794C2 (ru) 2006-12-28 2007-12-26 Применение 10-[(3r)-1-азабицикло[2.2.2]окт-3-илметил]-10н-фенотиазина для изготовления лекарства, селективно ингибирующего мускариновые рецепторы м1, м2 и м3
BRPI0720591-0A BRPI0720591A2 (pt) 2006-12-28 2007-12-26 Utilização da 10-[(3r)-1-azabiciclo[2.2.2.]oct-3-ilmetil]-10h-fenotiazin a para o preparo de um medicamento que exerce uma inibição seletiva dos receptores muscarínicos m1, m2, m3
UAA200907928A UA98131C2 (ru) 2006-12-28 2007-12-26 Применение 10-[(3r)-1-азабицикло[2.2.2] окт-3-илметил]-10h-фенотиазина для изготовления лекарства для профилактики или лечения недержания мочи
JP2009543465A JP5564263B2 (ja) 2006-12-28 2007-12-26 ムスカリンｍ１、ｍ２およびｍ３受容体の選択的阻害を有する薬剤の製造のための１０−［（３ｒ）−１−アザビシクロ［２．２．２］オクト−３−イルメチル］−１０ｈ−フェノチアジンの使用
US12/521,067 US8143245B2 (en) 2006-12-28 2007-12-26 Use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic M1, M2, and M3 receptors
CA002674162A CA2674162A1 (fr) 2006-12-28 2007-12-26 Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1,m2 et m3
MX2009006950A MX2009006950A (es) 2006-12-28 2007-12-26 Utilizacion de 10-[(3r)-1-azabiciclo[2.2.2]oct-3-ilmetil)-10h-feno tiazina, para la preparacion de un medicamento que ejerce una inhibicion selectiva de los receptores muscarinicos m1, m2 y m3.
NZ577915A NZ577915A (en) 2006-12-28 2007-12-26 Use of 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic m1, m2 and m3 receptors
AU2007341274A AU2007341274B2 (en) 2006-12-28 2007-12-26 Use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic M1, M2 and M3 receptors
HK10100843.7A HK1133207B (en) 2006-12-28 2007-12-26 Use of 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic m1, m2 and m3 receptors
PCT/EP2007/064553 WO2008080924A1 (fr) 2006-12-28 2007-12-26 Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylméthyl]-10h-phénothiazine pour la préparation d'un médicament exerçant une inhibition sélective des récepteurs muscariniques m1, m2 et m3
EP07858150A EP2124956A1 (fr) 2006-12-28 2007-12-26 Utilisation du 10-[(3r)-1-azabicyclo]2.2.2]oct-3-ylméthyl]-10h-phénothiazine pour la préparation d'un médicament exerçant une inhibition sélective des récepteurs muscariniques m1, m2 et m3
KR1020097013047A KR101465277B1 (ko) 2006-12-28 2007-12-26 무스카린 ｍ1, ｍ2 및 ｍ3 수용체 선택적 억제제 제조에 있어서의 10-[(3ｒ)-1-아자바이사이클로[2.2.2]옥트-3-일메틸]-10ｈ-페노티아진 용도
CN2007800467680A CN101573120B (zh) 2006-12-28 2007-12-26 10-[(3r)-1-氮杂双环[2.2.2]辛烷-3-基甲基]-10h-吩噻嗪在制备选择性抑制m1、m2和m3型毒蕈碱受体的药物中的用途
ARP070105989A AR064714A1 (es) 2006-12-28 2007-12-28 Utilizacion de 10-[ (3r)-1- azabiciclo [2..2..2] oct-3- ilmetil) -1 0h- fenotiazina, par a la preparacion de un medicamento que ejerce una inhibicion selectiva de los receptores muscarinicos m1,m2 y m3
ZA200904304A ZA200904304B (en) 2006-12-28 2009-01-01 Use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic M1, M2 and M3 receptors
TNP2009000257A TN2009000257A1 (fr) 2006-12-28 2009-06-23 Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1, m2 et m3.
IL199557A IL199557A (en) 2006-12-28 2009-06-25 Use of 10 [(r 3) -1-azabicyclo [2.2.2] oct-3-ilmethyl] - h 10 - phenazazine for the preparation of a drug with selective inhibition of muscarinic receptors 1m, 2m and 3m
MA32046A MA31026B1 (fr) 2006-12-28 2009-06-26 Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylméthyl]-10h-phénothiazine pour la préparation d'un médicament exerçant une inhibition sélective des récepteurs muscariniques m1, m2 et m3
NO20092654A NO20092654L (no) 2006-12-28 2009-07-13 Anvendelse av forbindelse
FR1152199A FR2953721A1 (fr) 2006-12-28 2011-03-17 Utilisation du 10-[(r3)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1, m2 et m3.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0656002A FR2910814B1 (fr) 2006-12-28 2006-12-28 Utilisation du 10-°(r3)-1-azabicyclo°2.2.2!oct-3-ylmethyl!-10h- phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1,2,3

Publications (2)

Publication Number Publication Date
FR2910814A1 FR2910814A1 (fr) 2008-07-04
FR2910814B1 true FR2910814B1 (fr) 2011-06-17

Family

ID=37951872

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0656002A Expired - Fee Related FR2910814B1 (fr) 2006-12-28 2006-12-28 Utilisation du 10-°(r3)-1-azabicyclo°2.2.2!oct-3-ylmethyl!-10h- phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1,2,3
FR1152199A Pending FR2953721A1 (fr) 2006-12-28 2011-03-17 Utilisation du 10-[(r3)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1, m2 et m3.

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR1152199A Pending FR2953721A1 (fr) 2006-12-28 2011-03-17 Utilisation du 10-[(r3)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1, m2 et m3.

Country Status (21)

Country Link
US (1) US8143245B2 (enExample)
EP (1) EP2124956A1 (enExample)
JP (1) JP5564263B2 (enExample)
KR (1) KR101465277B1 (enExample)
CN (1) CN101573120B (enExample)
AR (1) AR064714A1 (enExample)
AU (1) AU2007341274B2 (enExample)
BR (1) BRPI0720591A2 (enExample)
CA (1) CA2674162A1 (enExample)
FR (2) FR2910814B1 (enExample)
IL (1) IL199557A (enExample)
MA (1) MA31026B1 (enExample)
MX (1) MX2009006950A (enExample)
NO (1) NO20092654L (enExample)
NZ (1) NZ577915A (enExample)
RU (1) RU2449794C2 (enExample)
TN (1) TN2009000257A1 (enExample)
TW (1) TWI423806B (enExample)
UA (1) UA98131C2 (enExample)
WO (1) WO2008080924A1 (enExample)
ZA (1) ZA200904304B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015133989A (ja) * 2015-04-28 2015-07-27 重泉 達志 健康食品
KR101969263B1 (ko) 2018-07-16 2019-04-15 이상호 산소 챔버용 산소 공급 장치

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1173445B (it) * 1984-03-16 1987-06-24 Guidotti & C Spa Labor Agenti ad attivita' antibroncospastica e composizioni farmaceutiche che li contengono
IT1251161B (it) * 1991-08-07 1995-05-04 Derivati ammonio quaternari di (-) e (+)-3-(10 h-fenotiazin-10-ilmetil)-l-azabiciclo (2.2.2.)ottano e composizioni farmaceutiche che li contengono
AU6686700A (en) 1999-08-23 2001-03-19 H. Lundbeck A/S Treatment of urinary incontinence
AU2002366800B2 (en) * 2001-12-20 2006-08-03 Femmepharma Holding Company, Inc. Vaginal delivery of drugs

Also Published As

Publication number Publication date
US8143245B2 (en) 2012-03-27
JP2010514730A (ja) 2010-05-06
KR101465277B1 (ko) 2014-11-27
MX2009006950A (es) 2009-07-14
AR064714A1 (es) 2009-04-22
AU2007341274A1 (en) 2008-07-10
RU2009128326A (ru) 2011-02-10
JP5564263B2 (ja) 2014-07-30
RU2449794C2 (ru) 2012-05-10
FR2953721A1 (fr) 2011-06-17
AU2007341274B2 (en) 2012-09-20
HK1133207A1 (en) 2010-03-19
BRPI0720591A2 (pt) 2014-02-25
NZ577915A (en) 2011-12-22
CN101573120A (zh) 2009-11-04
TWI423806B (zh) 2014-01-21
UA98131C2 (ru) 2012-04-25
KR20090103887A (ko) 2009-10-01
TN2009000257A1 (fr) 2010-10-18
WO2008080924A1 (fr) 2008-07-10
NO20092654L (no) 2009-09-28
EP2124956A1 (fr) 2009-12-02
CN101573120B (zh) 2011-11-23
TW200833331A (en) 2008-08-16
FR2910814A1 (fr) 2008-07-04
ZA200904304B (en) 2010-06-30
CA2674162A1 (fr) 2008-07-10
US20100063276A1 (en) 2010-03-11
MA31026B1 (fr) 2009-12-01
IL199557A (en) 2014-09-30

Similar Documents

Publication Publication Date Title
WO2008072053A8 (en) Substituted arylpyrazoles
EP1971372A4 (en) CARRIER COMPOSITIONS WITH HYDROPHOBIC CORE FOR THE DELIVERY OF THERAPEUTIC AGENTS, MANUFACTURING AND USE METHODS THEREWITH
EP1759710A4 (en) MEANS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS
EP1895992A4 (en) PHARMACEUTICAL SYSTEMS COMPRISING COMPRESSIBLE KAUGUMMIBASIS FOR INGREDIENT RELIEF
EP1922019A4 (en) TRI-BLOCK COPOLYMERS FOR MEDICINAL DISPENSING ON NANO BEADS BASE
EP2152195A4 (en) PEPTIDATE MEDICINAL FOR ORAL LEVY
FR2913201B1 (fr) Protection pour couvrir l'extremite d'un dispositif d'administration ou d'un sous-ensemble,sous-ensemble et dispositif d'administration
EP2080383A4 (en) GENERIC INDICATION OF ADJUSTMENT GUIDE FOR SCALABLE MULTIMEDIA
FR2902010B1 (fr) Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique
EP1988048A4 (en) EVACUATION SUPPORT DEVICE FOR ELEVATOR
FR2925541B1 (fr) Element prefabrique pour unite d'habitation.
EP2269646A4 (en) PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST DIABETES OR ADIPOSITAS
EP2488207A4 (en) POLYMERIC ANTIBODY RELEASE SYSTEMS
EP1992354A4 (en) MEANS FOR THE PREVENTION OF RHEUMATOID ARTHRITIS FOR ORAL INJECTION
WO2007003411A3 (en) Kinin antagonists for treating bladder dysfunction
PL2319517T3 (pl) Wykorzystanie proleku do podawania doocznego, śródszklistkowego
EP2109424A4 (en) BIODEGRADABLE INTRAVAGINAL DEVICE FOR RELEASING THERAPEUTICS
FR2912915B1 (fr) Film a desintegration rapide pour l'administration buccale de substances actives.
WO2007115975A3 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
FR2900053B1 (fr) Utilisation du safranal, de la crocine, de la picrocrocine et leurs derives en tant qu'agent de satiete pour le traitement de la surcharge ponderale
FR2913677B1 (fr) Decapsuleur pour capsule de bouchage du col d'une bouteille.
FR2945217B1 (fr) Dispositif d'assistance a la phonation pour un patient tracheotomise.
FR2898272B1 (fr) Utilisation de derives du 3,5-seco-4-nor-cholestrane pour l'obtention d'un medicament cytoprotecteur
EP2098245A4 (en) USE OF CHOLINESTERASE FOR THE PREPARATION OF ANTI-TACHYKININ MEDICAMENT
FR2919744B1 (fr) Dispositif de restitution d'efforts pour un stimulateur de conduite.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160831